- Home
- TZOO vs SLS Comparison
TZOO vs SLS Comparison
Compare TZOO & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TZOO
- SLS
- Stock Information
- Founded
- TZOO 1998
- SLS 2012
- Country
- TZOO United States
- SLS United States
- Employees
- TZOO N/A
- SLS N/A
- Industry
- TZOO Advertising
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- TZOO Consumer Discretionary
- SLS Health Care
- Exchange
- TZOO Nasdaq
- SLS Nasdaq
- Market Cap
- TZOO 166.1M
- SLS 169.6M
- IPO Year
- TZOO 2002
- SLS N/A
- Fundamental
- Price
- TZOO $13.84
- SLS $1.71
- Analyst Decision
- TZOO Strong Buy
- SLS
- Analyst Count
- TZOO 4
- SLS 0
- Target Price
- TZOO $23.50
- SLS N/A
- AVG Volume (30 Days)
- TZOO 85.5K
- SLS 3.0M
- Earning Date
- TZOO 07-24-2025
- SLS 05-13-2025
- Dividend Yield
- TZOO N/A
- SLS N/A
- EPS Growth
- TZOO 11.63
- SLS N/A
- EPS
- TZOO 1.01
- SLS N/A
- Revenue
- TZOO $85,057,000.00
- SLS N/A
- Revenue This Year
- TZOO $16.82
- SLS N/A
- Revenue Next Year
- TZOO $25.91
- SLS N/A
- P/E Ratio
- TZOO $13.76
- SLS N/A
- Revenue Growth
- TZOO 0.23
- SLS N/A
- 52 Week Low
- TZOO $7.12
- SLS $0.77
- 52 Week High
- TZOO $24.85
- SLS $2.12
- Technical
- Relative Strength Index (RSI)
- TZOO 52.55
- SLS 54.26
- Support Level
- TZOO $12.86
- SLS $1.36
- Resistance Level
- TZOO $14.88
- SLS $2.12
- Average True Range (ATR)
- TZOO 0.58
- SLS 0.18
- MACD
- TZOO -0.03
- SLS -0.01
- Stochastic Oscillator
- TZOO 37.40
- SLS 46.05
About TZOO Travelzoo
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; and Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties. Most of the company's revenue is derived from North America.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.